3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
78
Prostatic Neoplasms, Castration-Resistant
3
Neoplasm Metastasis
3
Prostatic Diseases
2
Neoplasms
2
Genital Diseases, Male
2
Urogenital Neoplasms
1
Stage II Prostate Adenocarcinoma
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Prostate Cancer With ≤10 Bone Metastases
1
Prostate Cancer Metastatic Disease
1
Prostate Cancer Metastatic
1
Prostate Adenocarcinoma
1
Patient Preference
1
Newly Diagnosed Oligometastatic Prostate Cancer
1
Neoplasms by Site
1
Neoadjuvant Therapy
1
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
1
Metastatic Castration-sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Neoplasms
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Metastatic Castration-Resistant Prostate Cancer
1
Metastatic Castrate-sensitive Prostate Cancer
1
Low Risk Prostate Cancer
1
High-Risk and Oligometastatic Prostate Cancer
1
High Risk Prostate Cancer
1
Hematologic Neoplasms
1
Genital Neoplasms, Male
1
Castration Levels of Testosterone
1
Interventions
apalutamide
1
Receptors, Androgen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
High Risk Prostate Cancer
×
apalutamide
×
Clear all
NCT06758882
2025-01-06
STAPLE
A.O.U. Città della Salute e della Scienza
Phase 2
Recruiting
94 enrolled